Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck KGaA Changes Manager Incentives, But Stays Mum On Job Losses

This article was originally published in The Pink Sheet Daily

Executive Summary

Germany's Merck KGaA implements share-based incentive scheme for top management and vows to improve financial transparency, while discussing cost-savings with employees.

You may also be interested in...

Deals Of The Week: Merck KGaA/Symphogen, Valeant/Medicis, Medivir/Novadex

Achillion brought in nearly $42 million in its third large fundraising over the past 24 months, but the virology-focused biotech may become an increasingly sought acquisition target as other hepatitis C candidates face hurdles or are shelved entirely.

Merck KGaA Strengthens Anticancer Pipeline With Novel EGFR-Targeted Antibody Combination

A mixture of two antibodies that may have a novel synergistic effect against EGFR-expressing tumors has been licensed to Merck KGaA for development worldwide by Denmark's Symphogen, the recipient back in 2011 of one of the largest ever VC-backed financing rounds in Europe.

Merck KGAA Taps PDS For Cancer Vaccine Technology

The German pharma signs a deal with Indiana-based PDS Biotechnology that will use the company’s adjuvant technology to boost its own compounds.

Related Content


Related Companies

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts